Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b

NCT01860742 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT01860742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01860742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b
Lead sponsor
Jules Bordet Institute
Phase
Phase 3
Overall status
Withdrawn
Start date
December 31, 2014
Completion date
October 31, 2016
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastro-intestinal neuroendocrine tumors